Trial Profile

Phase 2a of SI-B001 in combination with osimertinib for patients with non-small cell lung cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Izalontamab (Primary) ; Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Sichuan Baili Pharmaceutical

Most Recent Events

20 May 2022 New trial record
13 May 2022 According to a SystImmune media release, the company and BAILI-BIOPHARMACEUTICAL CO., LTD announced that it has entered into a clinical trial collaboration and supply agreement with AstraZeneca to initiate this study. This study is sponsored and conducted by Baili.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com